Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
104,661,494
Total 13F shares
20,482,234
Share change
-51,094
Total reported value
$655,028,876
Price per share
$31.98
Number of holders
88
Value change
+$16,033,415
Number of buys
66
Number of sells
26

Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2015

As of 30 Jun 2015 Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) had 88 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions held a total of 20,482,234 shares of stock of the company.
Largest 10 holders included Essex Woodlands Health Ventures, Inc., NQ HCIF GP, Ltd., FRANKLIN RESOURCES INC, Bank of New York Mellon Corp, JPMORGAN CHASE & CO, Polar Capital LLP, BlackRock Fund Advisors, Arrowpoint Asset Management, LLC, VANGUARD GROUP INC, and WADDELL & REED FINANCIAL INC.
This table shows 88 institutional shareholders of the security as of 30 Jun 2015.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.